Back to Search
Start Over
[Hypertension: Who to treat, to what extent and how?]
- Source :
-
La Revue de medecine interne [Rev Med Interne] 2023 Apr; Vol. 44 (4), pp. 158-163. Date of Electronic Publication: 2023 Jan 27. - Publication Year :
- 2023
-
Abstract
- Hypertension is the modifiable risk factor causing the largest loss in healthy life-years. The risk of cardiovascular events increases exponentially with the level of blood pressure (BP), starting from 115mmHg for systolic BP. Out-of-office BP measurements (self-measurements or ambulatory BP measurements) are now preferred for the diagnosis and follow up. In the absence of a preferred indication, antihypertensive treatment is based on thiazide diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These treatments are associated with a significant reduction in morbidity and mortality in people with office BP ≥ 140/90mmHg (self-measurements ≥ 135/85mmHg). For people at high cardiovascular risk, especially those with a history of cardiovascular disease, starting the treatment for an office BP ≥ 130/80mmHg is also beneficial (self-measurements ≥ 130/80mmHg as well). It is now common to start treatment with half-dose dual therapy, which is more effective and better tolerated than full-dose monotherapy. The clinical effect is assessed at 4 weeks and intensification, if required, is then usually done by switching to the same dual therapy at full-dose for both components.<br /> (Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)
Details
- Language :
- French
- ISSN :
- 1768-3122
- Volume :
- 44
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- La Revue de medecine interne
- Publication Type :
- Academic Journal
- Accession number :
- 36710087
- Full Text :
- https://doi.org/10.1016/j.revmed.2023.01.008